BeiGene, Ltd. (NASDAQ:BGNE) Insider Lai Wang Sells 445 Shares

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) insider Lai Wang sold 445 shares of the business’s stock in a transaction dated Friday, June 17th. The stock was sold at an average price of $139.40, for a total value of $62,033.00. Following the transaction, the insider now directly owns 723 shares of the company’s stock, valued at approximately $100,786.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Lai Wang also recently made the following trade(s):

  • On Tuesday, June 21st, Lai Wang sold 723 shares of BeiGene stock. The stock was sold at an average price of $149.01, for a total value of $107,734.23.
  • On Monday, June 6th, Lai Wang sold 660 shares of BeiGene stock. The stock was sold at an average price of $142.00, for a total value of $93,720.00.

BGNE opened at $155.68 on Thursday. The stock has a market cap of $16.03 billion, a PE ratio of -7.75 and a beta of 0.87. The company has a current ratio of 5.05, a quick ratio of 4.87 and a debt-to-equity ratio of 0.03. BeiGene, Ltd. has a 1 year low of $118.18 and a 1 year high of $426.56. The stock’s 50 day simple moving average is $147.39 and its 200-day simple moving average is $198.61.

BeiGene (NASDAQ:BGNEGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.52) by $0.28. The business had revenue of $306.60 million for the quarter, compared to analysts’ expectations of $300.41 million. BeiGene had a negative return on equity of 40.10% and a negative net margin of 218.25%. The firm’s quarterly revenue was down 49.4% on a year-over-year basis. Equities analysts forecast that BeiGene, Ltd. will post -15.13 earnings per share for the current fiscal year.

Several research analysts have commented on the company. Morgan Stanley lifted their price target on BeiGene from $330.00 to $338.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. SVB Leerink downgraded BeiGene from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $300.00 to $177.00 in a research report on Thursday, March 17th. Finally, StockNews.com downgraded BeiGene from a “hold” rating to a “sell” rating in a research report on Thursday, June 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $315.33.

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in BeiGene by 77.1% in the 1st quarter. Bank of America Corp DE now owns 414,466 shares of the company’s stock valued at $78,169,000 after buying an additional 180,470 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in BeiGene by 155.4% in the first quarter. The Manufacturers Life Insurance Company now owns 20,175 shares of the company’s stock worth $4,010,000 after purchasing an additional 12,275 shares in the last quarter. Capital International Sarl boosted its stake in BeiGene by 38.3% in the first quarter. Capital International Sarl now owns 172,972 shares of the company’s stock worth $32,623,000 after purchasing an additional 47,918 shares in the last quarter. Capital Group International Inc. CA boosted its stake in BeiGene by 14.1% in the first quarter. Capital Group International Inc. CA now owns 1,140,960 shares of the company’s stock worth $215,185,000 after purchasing an additional 141,133 shares in the last quarter. Finally, Capital International Investors raised its position in shares of BeiGene by 11.2% during the first quarter. Capital International Investors now owns 7,055,295 shares of the company’s stock worth $1,337,378,000 after acquiring an additional 711,396 shares during the last quarter.

BeiGene Company Profile (Get Rating)

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Further Reading

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.